VetWatch reports lower vaccine and parasite-control spending. Vetsource’s US sample averaged fewer new puppy and kitten patients per practice in 2025. This edition also covers approval of Convenia RTU for Dogs, a survey on staff stress and an Accuplex test comparison. The focus is local demand, staff time and full costs before changing orders, services or tests.
Synchrony, Antech and Instinct announced links for clinic payments, test results and imaging reports. Digitail’s survey found that some users still move data by hand. Cronus announced US distribution of Florfinasone Otic for certain outer ear infections in dogs. This edition focuses on full task times, software limits and buying costs before clinics change systems or orders.
IDEXX bought CoVetAI and plans clinic software links. Loyal reports that the US Food and Drug Administration accepted an LOY-003 effectiveness section; approval remains undecided. Nationwide expanded VetHelpline visits with possible prescriptions in 11 states and the District of Columbia. Vetology says it rebuilt 94 X-ray screening models. The Edition focuses on note handoffs, fill requests and X-ray review time.
PetMeds reported a 19.9% net sales fall and lower cash. Simparica TRIO received FDA emergency authorization to treat screwworm in dogs, while language models missed cases surgeons classified for surgery. This edition also covers IDEXX’s planned Cancer Dx additions, Battery Ventures’ Vetspire investment and copyright suits alleging unlicensed image use by veterinary practices.
Two US practice data samples showed more revenue while visit, client, invoice or patient counts fell. US pet insurers wrote more direct premiums in 2025; Merck and Hill’s global sales rose in the second quarter. American Regent recalled 2 Adequan Canine lots after it found glass fibers.
CVS pages conflicted on pet-prescription availability, and Texas added three screwworm zones and revised Zone 14.A. This edition also covers FDA animal-drug manufacturing incentives, Four Corners’ purchase of 102 Mission-operated properties, and Virbac companion animal growth alongside lower total North American revenue.
